Mico BioMed Co. Ltd. (214610) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has a cash flow conversion efficiency ratio of -0.315x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-8.13 Billion ≈ $-5.51 Million USD) by net assets (₩25.81 Billion ≈ $17.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Mico BioMed Co. Ltd. balance sheet independence to measure how much of total assets are equity-financed.
Mico BioMed Co. Ltd. - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Mico BioMed Co. Ltd. to evaluate the quality of earnings relative to operating cash generation.
Mico BioMed Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Arrive AI Inc.
NASDAQ:ARAI
|
-1.222x |
|
Big Pharma Split Corp Class A
TO:PRM
|
-0.011x |
|
ICH Co Ltd
KQ:368600
|
-0.014x |
|
Nam Sung
KO:004270
|
-0.009x |
|
Volcano Bhd
KLSE:0232
|
0.027x |
|
Pivotal Metals Ltd
AU:PVT
|
-0.038x |
|
Ganges Securities Limited
NSE:GANGESSECU
|
0.029x |
|
See Hup Consolidated Bhd
KLSE:7053
|
0.028x |
Annual Cash Flow Conversion Efficiency for Mico BioMed Co. Ltd. (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mico BioMed Co. Ltd. from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Mico BioMed Co. Ltd..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩25.89 Billion ≈ $17.54 Million |
₩-10.70 Billion ≈ $-7.25 Million |
-0.413x | -32.16% |
| 2023-12-31 | ₩36.33 Billion ≈ $24.62 Million |
₩-11.36 Billion ≈ $-7.70 Million |
-0.313x | +60.50% |
| 2022-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-14.01 Billion ≈ $-9.49 Million |
-0.792x | -381.03% |
| 2021-12-31 | ₩52.26 Billion ≈ $35.42 Million |
₩-8.60 Billion ≈ $-5.83 Million |
-0.165x | +50.70% |
| 2020-12-31 | ₩55.96 Billion ≈ $37.92 Million |
₩-18.68 Billion ≈ $-12.66 Million |
-0.334x | +96.73% |
| 2019-12-31 | ₩1.02 Billion ≈ $691.72K |
₩-10.43 Billion ≈ $-7.07 Million |
-10.223x | -759.39% |
| 2018-12-31 | ₩5.71 Billion ≈ $3.87 Million |
₩-6.79 Billion ≈ $-4.60 Million |
-1.190x | -40.61% |
| 2017-12-31 | ₩3.42 Billion ≈ $2.32 Million |
₩-2.89 Billion ≈ $-1.96 Million |
-0.846x | +18.99% |
| 2016-12-31 | ₩3.83 Billion ≈ $2.59 Million |
₩-3.99 Billion ≈ $-2.71 Million |
-1.044x | -- |
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more